Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 5353
115th Congress(2017-2018)
Eliminating Opioid Related Infectious Diseases Act of 2018
Active
Active
Passed House on Jun 12, 2018
Overview
Text
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 5353 (Introduced-in-House)


115th CONGRESS
2d Session
H. R. 5353


To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

IN THE HOUSE OF REPRESENTATIVES

March 20, 2018

Mr. Lance (for himself, Mr. Kennedy, Mr. Collins of New York, Ms. Eshoo, Mr. Barton, and Ms. Matsui) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Eliminating Opioid Related Infectious Diseases Act of 2018”.

SEC. 2. Reauthorization and expansion of program of surveillance and education regarding infections associated with injection drug use.

Section 317N of the Public Health Service Act (42 U.S.C. 247b–15) is amended to read as follows:

“SEC. 317N. Surveillance and education regarding infections associated with injection drug use.

“(a) In general.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may (directly and through grants to public and nonprofit private entities) provide for programs to carry out the following activities:

“(1) To cooperate with the States in implementing a surveillance system to determine the incidence of infections associated with injection drug use and to assist the States in determining the prevalence of such infections, including the reporting of chronic hepatitis C virus and human immunodeficiency virus cases.

“(2) To identify, counsel, and offer testing to individuals who are at risk of infections as a result of injection drug use, receiving blood transfusions prior to July 1992, or other risk factors.

“(3) To provide appropriate referrals for counseling, testing, and medical treatment of individuals identified under paragraph (2) and to ensure, to the extent practicable, the provision of appropriate follow-up services.

“(4) To develop and disseminate public information and education programs for the detection and control of infections associated with injection drug use, with priority given to high-risk populations as determined by the Secretary.

“(5) To improve the education, training, and skills of health professionals in the detection and control of infections associated with injection drug use, with priority given to substance use disorder treatment providers, pediatricians, other primary care providers, and obstetrician-gynecologists.

“(b) Laboratory procedures.—The Secretary may (directly and through grants to public and nonprofit private entities) carry out programs to provide for improvements in the quality of clinical-laboratory procedures regarding infections associated with injection drug use.

“(c) Definitions.—In this section, the term ‘injection drug use’ means—

“(1) intravenous administration of a substance in schedule I under section 202 of the Controlled Substances Act;

“(2) intravenous administration of a substance in schedule II, III, IV, or V under section 202 of the Controlled Substances Act that has not been approved for intravenous use under—

“(A) section 505 of the Federal Food, Drug and Cosmetic Act; or

“(B) section 351 of the Public Health Service Act; or

“(3) intravenous administration of a substance in schedule II, III, IV, or V under section 202 of the Controlled Substances Act that has not been prescribed to the person using the substance.

“(d) Authorization of appropriations.—For the purpose of carrying out this section, there are authorized to be appropriated $40,000,000 for each of the fiscal years 2019 through 2023.”.